C.I. MedicalLtd Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de C.I. MedicalLtd de 18.3% y 11.3% por año respectivamente. Se prevé que el BPA crezca en un 18.3% al año. Se espera que la rentabilidad financiera sea de 13.5% en 3 años.

Información clave

18.3%

Tasa de crecimiento de los beneficios

18.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	8.9%
Tasa de crecimiento de los ingresos	11.3%
Rentabilidad financiera futura	13.5%
Cobertura de analistas	Low
Última actualización	15 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Introducing C.I. MedicalLtd (TYO:3540), The Stock That Zoomed 114% In The Last Year

Feb 18

Should You Be Adding C.I. MedicalLtd (TYO:3540) To Your Watchlist Today?

Jan 31

Can C.I. MedicalLtd (TYO:3540) Keep Up These Impressive Returns?

Jan 13

Could The Market Be Wrong About C.I. Medical Co.,Ltd. (TYO:3540) Given Its Attractive Financial Prospects?

Dec 26

Is C.I. Medical Co.,Ltd. (TYO:3540) Potentially Undervalued?

Dec 08

Can You Imagine How Jubilant C.I. MedicalLtd's (TYO:3540) Shareholders Feel About Its 118% Share Price Gain?

Nov 20

The C.I. MedicalLtd (TYO:3540) Share Price Is Up 60% And Shareholders Are Holding On

Jul 07

Previsiones de crecimiento de beneficios e ingresos

TSE:3540 - Estimaciones futuras de los analistas y datos financieros pasados (JPY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	64,000	3,600	N/A	3,430	1
12/31/2025	56,000	2,950	N/A	2,050	1
12/31/2024	50,000	2,430	N/A	247	1
12/31/2023	45,628	2,082	-9,086	-156	N/A
9/30/2023	45,071	2,162	N/A	N/A	N/A
6/30/2023	44,125	2,219	-4,594	1,090	N/A
3/31/2023	43,473	2,173	N/A	N/A	N/A
12/31/2022	42,891	2,521	-7,939	1,409	N/A
9/30/2022	42,073	2,709	N/A	N/A	N/A
6/30/2022	41,754	2,798	-4,720	2,077	N/A
3/31/2022	41,142	2,815	N/A	N/A	N/A
12/31/2021	41,205	2,820	-1,253	1,578	N/A
9/30/2021	41,500	3,182	N/A	N/A	N/A
6/30/2021	40,833	3,334	4,083	4,497	N/A
3/31/2021	39,593	3,309	N/A	N/A	N/A
12/31/2020	37,393	2,920	3,701	4,159	N/A
9/30/2020	33,251	2,263	N/A	N/A	N/A
6/30/2020	31,964	1,924	211	473	N/A
3/31/2020	30,265	1,608	N/A	N/A	N/A
12/31/2019	28,763	1,505	1,144	1,402	N/A
9/30/2019	28,876	1,571	N/A	N/A	N/A
6/30/2019	26,898	1,345	613	1,127	N/A
3/31/2019	26,484	1,414	N/A	N/A	N/A
12/31/2018	25,806	1,329	212	722	N/A
9/30/2018	24,892	1,358	N/A	N/A	N/A
6/30/2018	24,323	1,458	1,340	1,579	N/A
3/31/2018	23,336	1,445	N/A	N/A	N/A
12/31/2017	22,830	1,539	719	1,006	N/A
9/30/2017	21,999	1,486	N/A	N/A	N/A
6/30/2017	21,440	1,497	N/A	491	N/A
3/31/2017	20,887	1,390	N/A	781	N/A
12/31/2016	20,334	1,282	N/A	1,071	N/A
12/31/2015	18,145	1,088	N/A	N/A	N/A
12/31/2014	16,084	901	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.3% al año) de 3540 es superior a la tasa de ahorro (0.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (18.3% al año) de 3540 crezcan más rápidamente que el mercado JP (9.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 3540 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (11.3% al año) de 3540 crezcan más rápidamente que los del mercado JP (4.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 11.3% al año) de 3540 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 3540 sea baja dentro de 3 años (13.5%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

C.I. MedicalLtd Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 16%, revenue upgraded

Price target decreased to JP¥4,300

Price target decreased to JP¥5,300

Analysts increase EPS estimates to JP¥320

Analysts increase EPS estimates to JP¥251

Recent updates

C.I. Medical Co.,Ltd., Annual General Meeting, Mar 26, 2024

Full year 2023 earnings released: EPS: JP¥208 (vs JP¥252 in FY 2022)

C.I. Medical Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 13, 2024

Upcoming dividend of JP¥25.00 per share at 0.6% yield

Investor sentiment improves as stock rises 15%

New major risk - Financial position

Third quarter 2023 earnings released: EPS: JP¥51.29 (vs JP¥57.01 in 3Q 2022)

C.I. Medical Co.,Ltd. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: JP¥70.50 (vs JP¥65.91 in 2Q 2022)

C.I. Medical Co.,Ltd. to Report Q2, 2023 Results on Aug 08, 2023

First quarter 2023 earnings released: EPS: JP¥52.10 (vs JP¥86.91 in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Now 23% undervalued after recent price drop

Consensus EPS estimates fall by 16%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

C.I. Medical Co.,Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Upcoming dividend of JP¥28.50 per share

Third quarter 2022 earnings released: EPS: JP¥57.01 (vs JP¥65.91 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥56.99 (vs JP¥65.91 in 3Q 2021)

C.I. Medical Co.,Ltd. (TSE:3540) agreed to acquire Naiki Shiken Ltd. from Yuichi Naiki and Yuriko Naiki.

C.I. Medical Co.,Ltd. to Report Q3, 2022 Results on Nov 08, 2022

C.I. Medical Co.,Ltd. (TSE:3540) agreed to acquire Sakura Dental Laboratory from Akira Ochi and Katsumi Ochi.

Second quarter 2022 earnings released: EPS: JP¥65.90 (vs JP¥67.61 in 2Q 2021)

C.I. Medical Co.,Ltd. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to JP¥4,300

C.I. Medical Co.,Ltd. to Report Q1, 2022 Results on May 10, 2022

Investor sentiment improved over the past week

C.I. Medical Co.,Ltd., Annual General Meeting, Mar 24, 2022

Full year 2021 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Price target decreased to JP¥5,300

Third quarter 2021 earnings released: EPS JP¥65.89 (vs JP¥81.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥67.61 (vs JP¥65.10 in 2Q 2020)

Investor sentiment deteriorated over the past week

Looop Inc. agreed to acquire 60% stake in Niigata Prefectural Electric Power Co., Ltd. and Yotsuba Electric Power Co., Ltd. from C.I. Medical Co.,Ltd. (JASDAQ:3540).

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS JP¥87.40 (vs JP¥48.50 in 1Q 2020)

Here's Why We Think C.I. MedicalLtd (TYO:3540) Is Well Worth Watching

Returns on Capital Paint A Bright Future For C.I. MedicalLtd (TYO:3540)

Full year 2020 earnings released: EPS JP¥292 (vs JP¥151 in FY 2019)

Investor sentiment improved over the past week

Should You Investigate C.I. Medical Co.,Ltd. (TYO:3540) At JP¥5,450?

New 90-day low: JP¥5,490

Analysts increase EPS estimates to JP¥320

Introducing C.I. MedicalLtd (TYO:3540), The Stock That Zoomed 114% In The Last Year

C.I. Medical Co.,Ltd. (JASDAQ:3540) acquired 22.4% stake in Fuji Dental Lab Co., Ltd.

Full year 2020 earnings released: EPS JP¥292 (vs JP¥151 in FY 2019)

Revenue and earnings beat expectations

Should You Be Adding C.I. MedicalLtd (TYO:3540) To Your Watchlist Today?

Yosuke Oda Kaki and Keisuke Hori agreed to acquire an additional 60% stake in One Recto Holdings Co., Ltd. from C.I. Medical Co.,Ltd. (JASDAQ:3540).

New 90-day low: JP¥5,900

Can C.I. MedicalLtd (TYO:3540) Keep Up These Impressive Returns?

C.I. Medical Co.,Ltd. to Report Fiscal Year 2020 Results on Feb 21, 2021

Could The Market Be Wrong About C.I. Medical Co.,Ltd. (TYO:3540) Given Its Attractive Financial Prospects?

Upcoming Dividend of JP¥15.00 Per Share

New 90-day low: JP¥6,150

Is C.I. Medical Co.,Ltd. (TYO:3540) Potentially Undervalued?

New 90-day low: JP¥6,520

Analysts increase EPS estimates to JP¥251

Can You Imagine How Jubilant C.I. MedicalLtd's (TYO:3540) Shareholders Feel About Its 118% Share Price Gain?

Third quarter 2020 earnings released: EPS JP¥81.10

Revenue and earnings beat expectations

C.I. Medical Co.,Ltd. (JASDAQ:3540) reached an agreement to acquire 60% stake in Niigata Prefectural Electric Power Co., Ltd. from Takashi Kakuya, Chairman and Director of Niigata Prefectural Electric Power Co., Ltd.

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS JP¥81.10

New 90-day high: JP¥8,810

C.I. Medical Co.,Ltd. to Report Q3, 2020 Results on Nov 10, 2020